Rob Dicicco

Rob DiCicco is the Vice President, Portfolio Management at TransCelerate Biopharma, Inc. Rob joined TransCelerate from IBM Watson Health where he was the Deputy Chief Health Officer. At IBM he worked closely with software designers and developers to inform product roadmaps. Rob also conducted research to assess the performance of solutions applied in the e-clinical environment.

Prior to joining IBM, Rob had a long career with GlaxoSmithKline where he served in a variety of leadership positions. While at GSK, Rob was the Vice President of Clinical Pharmacology Sciences and Study Operations with a global footprint that included the US, UK, Australia, and China. Rob’s team designed clinical trials aimed at profiling new medicines, establishing proof of concept, and delivering critical data for product labelling. He also led the development a number of late-phase oncology projects leading to successful product approvals. In 2015, Rob launched a Clinical Innovation and Digital Platforms Team at GSK where he focused on identifying, evaluating, and piloting emerging technical solutions to automate different areas of clinical trial design and implementation. Under his leadership, Rob’s team launched the first industry-sponsored Apple Research Kit Study to assess disease burden in rheumatoid arthritis patients in a real-world setting. In addition to his GSK responsibilities, Rob also led TransCelerate’s Common Protocol Template and Digital Data Flow workstreams. He was also one of the team leads for the Clinical Trials Transformation Initiative (CTTI) sponsored Mobile Clinical Trials Novel Endpoints project.

Rob received his Doctor of Pharmacy Degree from the University of the Sciences in Philadelphia. His areas of expertise and interest include clinical trial design, clinical operations, protocol quality, and ethics in research.